Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum CytomX Therapeutics Inc CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more

NDAQ:CTMX - Post Discussion

CytomX Therapeutics Inc > CTMX Price Target Alert: $8.00. Issued by Jefferies
View:
Post by whytestocks on May 06, 2024 12:30am

CTMX Price Target Alert: $8.00. Issued by Jefferies

Just In: $CTMX CTMX Price Target Alert: $8.00. Issued by Jefferies2024-05-06 00:00:04 ET Roger Song from Jefferies issued a price target of $8.00 for CTMX on 2024-05-05 19:42:00. The adjusted price target was set to $8.00. At the time of the announcement, CTMX was trading at $4.455. The overall price target consensus is at $5.63 with h...CTMX - CTMX Price Target Alert: $8.00. Issued by Jefferies
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities